<code id='3281A8F841'></code><style id='3281A8F841'></style>
    • <acronym id='3281A8F841'></acronym>
      <center id='3281A8F841'><center id='3281A8F841'><tfoot id='3281A8F841'></tfoot></center><abbr id='3281A8F841'><dir id='3281A8F841'><tfoot id='3281A8F841'></tfoot><noframes id='3281A8F841'>

    • <optgroup id='3281A8F841'><strike id='3281A8F841'><sup id='3281A8F841'></sup></strike><code id='3281A8F841'></code></optgroup>
        1. <b id='3281A8F841'><label id='3281A8F841'><select id='3281A8F841'><dt id='3281A8F841'><span id='3281A8F841'></span></dt></select></label></b><u id='3281A8F841'></u>
          <i id='3281A8F841'><strike id='3281A8F841'><tt id='3281A8F841'><pre id='3281A8F841'></pre></tt></strike></i>

          Home / entertainment / focus

          focus


          focus

          author:hotspot    Page View:2888
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In